Dr. Jonathan Mizrahi and Dr. Jun Gong highlight how ctDNA is increasingly used to assess recurrence risk after surgery in colorectal cancer, while emphasizing that transient clearance does not always equate to cure. Practical considerations around which patients benefit most from molecular monitoring are explored. The discussion also reviews emerging immunotherapy–TKI combinations showing early survival signals in microsatellite-stable, heavily pretreated disease. Together, these advances point toward more personalized surveillance and expanding treatment options in colorectal cancer.
Contributors:
Dr. Jonathan Mizrahi is a medical oncologist with Ochsner Health in New Orleans, Louisiana.
Dr. Jun Gong is an oncologist at Cedars-Sinai in Los Angeles, California.
